
This article was downloaded by: [Laurentian University]

On: 16 April 2013, At: 06:08 Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH,

UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/gpss20

Synthesis of New Fused 1,5-Benzodiazepines, Part 3

A. Khodairy ^a

^a Chemistry Department, Faculty of Science, Sohag, Egypt

Version of record first published: 18 Aug 2006.

To cite this article: A. Khodairy (2005): Synthesis of New Fused 1,5-Benzodiazepines, Part 3, Phosphorus, Sulfur, and Silicon and the Related Elements, 180:8, 1893-1907

To link to this article: http://dx.doi.org/10.1080/104265090889611

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.tandfonline.com/page/terms-and-conditions

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Phosphorus, Sulfur, and Silicon, 180:1893–1907, 2005

Copyright © Taylor & Francis Inc. ISSN: 1042-6507 print / 1563-5325 online

DOI: 10.1080/104265090889611



Synthesis of New Fused 1,5-Benzodiazepines, Part 3*

A. Khodairy

Chemistry Department, Faculty of Science, Sohag, Egypt

1,3-Dihydro-4-phenyl-1,5-benzodiazepin-2-one 1_a was treated with some ylidenecyanothioacetamides to give the corresponding pyrido(2,3-b)benzodiazepines 3-6. Treatment of compound 1_a with a mixture of thiophen-2-aldehyde and thiourea or guanidine gave the corresponding 1,3-thiazino- and pyrimido(4,5-b)benzodiazepines 7 and 8. 3-Arylidene derivatives 9_{a-e} and 10 were synthesized. Compound 10 was subject to react with 2-(1-methylthio-1'-anilinomethylidene)malononitrile to give oxazino-benzodiazepine 11. Thieno(3,2-b)benzodiazepines $12_{a,b}$ and 13 were synthesized via the reaction of compound 1_b with sulfur and some active nitriles. [1,3-Dihydro-4-phenyl(1,5)-benzodiazepin-2-ylidene|malononitrile 15 was used as synthon to obtain novel pyrido-, pyrano-, benzo-, and thienobenzodiazepines 16-20, respectively. The reaction of compound 1_b with CS_2 or PhNCS along with 1,1,3-tricyano-2-aminoprop-1-ene, 2-(1-methylthio-1'-anilinomethylidene)malononitrile, or 1,3-dibromopropane gave the corresponding polyfused benzodiazepines 21-23, respectively.

Keywords 1,3-Dihydro-4-phenyl-1,5-benzodiazepin-2-one; pyridobenzodiazepines; pyrimidobenzodiazepines; thiazinobenzodiazepines; oxazinobenzodiazepines; thienobenzodiazepines

INTRODUCTION

Benzodiazepines have been widely employed in clinical practices as anxiolytics, ¹ sedative-hypnotics, ² anticonvulsant vasopressin antagonists, ³ and anticipated CNS-depressants. ⁴ Interestingly, benzothienobenzodiazepine (Y-931), dibenzo[b,f]diazepine (clozapine), and thienobenzodiazepine (olanzapine) are known as typical effective antipsychotics. ^{5,6}

This prompted us to continuate our previous work^{7,8} to synthesize some new fused and spiro benzodiazepines. So, we report herin the synthesis of novel pyridine, pyran, thiophene, pyrimidine, oxazine, thiazine, and naphthyridine rings fused with benzodiazepine moiety.

Received June 6, 2004; accepted September 7, 2004.

*For Part 1 and Part 2, see references 7 and 8.

Address correspondence to A. Khodairy, Chemistry Department, Faculty of Science, Sohag, 82524 Egypt. E-mail: khodairy@yahoo.com

SCHEME 1

RESULTS AND DISCUSSION

The reaction of 1,3-dihydro-4-phenyl-1,5-benzodiazepin-2-one $\mathbf{1}_a^9$ with a variety of arylidenecyanothioacetamides namely; benzo[b]-3,4dioxolmethylidene-, p-fluorobenzylidene-, thien-2-ylidene-, or pyrrol-2-ylidenecyanothioacetamide in the presence of piperidine as a catalyst, afforded the corresponding 3-substituted benzodiazepines 2_{a-d} , which in turn were cyclized in the presence of sodium ethoxide to afford 3-cyano-pyrido[2,3-b][1,5]benzodiazepine-2-thione derivatives $\mathbf{3}_{\mathbf{a-d}}$. Compounds $\mathbf{3}_{\mathbf{a-d}}$ and 4 were also prepared in one step via the reaction of compound 1a with the same arylidenecyanothioacetamides or cyclohexylidenecyano thio-acetamide in alcoholic sodium ethoxide. IR spectra of compounds 2_{a-d} showed the absorption bands corresponding to NH₂, CN, and C=O groups at 3320, 3200, 2210, and 1690 Cm⁻¹, respectively, whereas IR spectra of compounds 3_{a-d} and 4 showed the disappearance of the absorption bands corresponding to NH₂ and C=O groups and the appearance of the absorption bands corresponding to NH groups (cf. Scheme 2, Table I). Compound 3a was treated with some active halo compounds, namely ethyl chloroacetate, chloroacetonitrile, phenacyl bromide, or chloroacetanilide, in the presence of sodium acetate, to afford the corresponding S-alkylated derivatives 5_{a-d}. Compound 5_a underwent intramolecular cyclization, ¹⁰ affording the corresponding thieno[3',2':5,6]pyrido[2,3-b]-1,5-benzodiazepine derivative 6 on refluxing with sodium ethoxide. IR spectrum of compound 6 showed the disappearance of the absorption band corresponding to the CN group and ¹H-NMR spectrum revealed a broad signal at δ 5.4–5.0 of the NH₂ group, which was exchangeable with deuterium on addition of D₂O (c.f. Scheme 2, Table I).

Treatment of compound 1_a with a mixture of thiophen-2-aldehyde and thiourea or guanidine in the presence of sodium methoxide¹¹ gave the corresponding 1,3-thiazino- and pyrimido[4,5-b][1,5]benzodiazepine derivatives **7** and **8**, respectively (c.f. Scheme 2, Table I).

SCHEME 2

3-Arylidene-1,5-benzodiazepine derivatives $\mathbf{9_{a-e}}$ and $\mathbf{10}$ were synthesized through the reaction of compound $\mathbf{1_a}$ with some aromatic carbonyl reagents including o-, m-, and p-chlorobenzaldehyde; p-nitrobenzaldehyde; p-N,N-dimethylaminobenzaldehyde; or isatine in glacial acetic acid and fused sodium acetate as a catalyst. Compound $\mathbf{10}$ was subjected to react with 2-(1-methylthio-1'-anilinomethylidene)malononitrile¹² in *tert*. butanol to afford the corresponding 1,3-oxazine[6,5-b](1,5)benzodiazepine derivative $\mathbf{11}$. IR spectrum of

TABLE I Analytical and Spectral Data of the New Compounds

Product	$M \mathbf{P} (\circ \mathbf{C})^a$	Vield	Mol form	Analyti	ical dat	Analytical data (cal./found) ^b	q(punc		
no	ວ	(%)	(mol. w.t.)	C	Н	Z	∞	IR $(\mathrm{Cm}^{-1})^c$	$\text{H-NMR}\ (\delta\ \text{ppm})^d$
2a	166 (EtOH)	80	$C_{26}H_{20}N_4O_3S$ (468.53)	66.50 66.77	4.30	11.96	6.84	3433, 3366, 3211(NH, NH ₂), 2214(CN), 1898 (CO), 1432(CS).	10.2(s, 1H, NH), 8.0–7.3(m, 12H, arom.), 6.3(m, 1H, CH—Ar), 7.0[br, 1H, CH(CN)], 5.5–5.2(br, 2H, NH ₂), 4.0(s, 2H, CH ₂), 3.5(d.
S ₂	187 (Dioxane)	86	$ m C_{25}H_{19}FN_4OS \ (442.51)$	67.86	4.33	12.66	7.25	$3321, 3300, 3201 (\mathrm{NH}, \mathrm{NH}_2), 2224 (\mathrm{CN}), 1890 (\mathrm{CO}), 1430 (\mathrm{CS}).$	1H, CHbenzdiazepine). 10.0(s, 1H, NH), 8.1–7.5(m, 13H, arom.), 6.2(t, 1H, CH—Ar), 7.2[br, 1H, CH(CN)], 55.1(hr, 9H, NH), 3.8(d)
$^{2}_{c}$	177 (Acetic acid)	06	$C_{23}H_{18}N_4OS_2 \ (430.54)$	64.16 64.32	4.21	13.01 13.32	14.89	$3400, 3326, 3241(\mathrm{NH}, \mathrm{NH}_2), 2240(\mathrm{CN}), 1893 (\mathrm{CO}), 1442(\mathrm{CS}).$	11, CH _{benzodiasepine} . 10.0(s, 1H, NH), 8.2–7.7(m, 12H, arom.), 6.0(m, 1H, CH—Ar), 5.3–5.0(br, 2H, NH2), 3.7(d)
$2_{ m d}$	219 (DMF)	99	$ ext{C}_{23} ext{H}_{19} ext{N}_5 ext{OS} \ (413.50)$	66.81 66.93	4.30	16.94	7.75	3344, 3312, 3265(2NH, NH2), 2211(CN), 1700 (CO), 1422(CS).	1H, CH _{benzodiazepine}). 10.2(s, 1H, NH), 9.2(s, 1H, NH) p.27(s, 1H, NH) arom.), 6.1(m, 1H, CH-Ar), 5.7[br, 1H, CH(CN)].
ဗု က်	290 (Dioxane) 266	85 85	$egin{array}{c} { m C}_{26}{ m H}_{16}{ m N}_4{ m O}_2{ m S} \ (448.5) \ { m C}_{25}{ m H}_{15}{ m FN}_4{ m O} \end{array}$	69.63 69.43 71.07	3.60 3.43 3.58	12.49 12.51 13.26	7.15 7.34 7.59	3333, 3200(NH), 2242 (CN), 1430(CS). 3321, 3211(NH), 2211	D.5-4.3(Df, ZH, NH2), 5.5(d, 1H, CH _{benz.}) 13.4(s, 1H, NH), 10.0(s, 1H, NH), 8.2-7.1 (m, 13H, arom.). 12.4(s, 1H, NH), 9.4(s, 1H, NH),
2	(EtOH)		(422.48)	71.23	3.30	13.42	7.32	(CN), 1436(CS).	8.3–7.6 (m, 12H, arom.).

10.4(s, 1H, NH), 9.4(s, 1H, NH), 8.3–7.7 (m, 12H, arom.).	11.4(s, 1H, NH), 9.9(s, 1H, NH), 8.0–7.1 (m, 12H, arom.).	12.4(s, 1H, NH), 8.4(s, 1H, NH),	5.9-7.8 (m, 911, aroun.), 5.96s, 1H, CH, CN), 3.0-1.0(m, 10H, 5CH ₂).	11.0(s, 1H, NH), 8.3–7.7(m, 12H, arom.), 4.2(s, 2H, SCH _o).	$4.0(s, 2H, CH_2)$.	13.0(s, 1H, NH), 8.0–7.4(m,	12H, arom.), 4.4–4.3(m, 4H,	$CH_{2 \text{ ester}} + SCH_{2}), 3.9(s, 2H,$	CH_2) 1.3–1.1(t, 3H, CH_3).	9.0(s, 1H, NH), 8.3-7.7(m, 17H,	arom.), $4.0(s, 2H, SCH_2)$,	$3.7(s, 2H, SCH_2).$	9.0(s, 1H, NH), 8.3-7.7(m, 17H,	arom. $+ NH$), 4.0(s, 2H, CH_2),	$3.7(s, 2H, SCH_2).$	10.0(s, 1H, NH), 8.4–7.4(m, 12H,	arom.), $6.0-5.5(br, 2H, NH_2)$,	$4.4-4.3(q, 2H, CH_{2 \text{ ester}}), 3.9(s, 2H, CH_{2 \text{ ester}})$	ZH , CH_2) $L.3-L.1(\mathbb{t}$, $3H$, CH_3).	arom.), $5.4-5.0(\text{br}, 2\text{H}, \text{NH}_2)$.
3300, 3241(NH), 2251 (CN), 1440(CS).	3341, 3231(NH), 2231 (CN), 1432(CS).	3266, 3200(2NH), 2133	(CN), 1444(CD).	6.00 3280(NH), 2233(CN). 6.23		3220(NH), 2143(CN),	1734(CO).			3224(NH), 2220 (CN),	1690 (CO).		3210, 3122(2NH), 2218	(CN), 1690 (CO).		3421, 3350, 3210(NH,	NH_2), 1734(CO).		3344 3900	$3182({ m NH} + { m NH}_2).$
15.62 15.78	8.15	8.08	0.60	6.00		6.58	6.43			5.66	5.87		5.51	5.78		00.9	6.12		18 50	16.81
13.65 13.48	17.80 17.69	14.06	14.01	10.48			14.49			68.6	9.71		12.04	12.24		10.48	10.57		17 70	14.48
3.44	3.84	5.56	0.70	4.15		3.51	3.70			3.91	3.72		3.99	3.85		4.15	4.33		7	4.36
67.30 67.43	70.21	72.33	17.77	67.40 67.43		88.88	68.64			72.07	72.33		70.21	70.43		67.40	99.79		64 00	64.62
$\substack{\text{C}_{23}\text{H}_{14}\text{N}_4\text{S}_2\\(410.00)}$	$C_{23}H_{15}N_5S = (393.46)$	$C_{24}H_{22}N_4S$	(990.97)	$\mathrm{C}_{30}\mathrm{H}_{22}\mathrm{N}_4\mathrm{O}_4\mathrm{S}$ (534.59)		$\mathrm{C}_{28}\mathrm{H}_{17}\mathrm{N}_5\mathrm{O}_2\mathrm{S}$	(487.53)			${ m C}_{34}{ m H}_{22}{ m N}_4{ m O}_3{ m S}$	(566.63)		${ m C}_{34}{ m H}_{23}{ m N}_5{ m O}_3{ m S}$	(581.65)		$ m C_{30}H_{22}N_4O_4S$	(534.59)		S.N.H.	(388.50)
71	29	89		69		64				44			92			20			O	8
270 (DMF)	240-3 (DMF)	222 (F+OH)	(ECOII)	220 (EtOH)		210	(Benzene)			222	(EtOH)		238	(DMF)		>330	(DMF)		308	(Dioxane)
ຕິ	3	4		5_{a}		$5_{ m b}$				ي			$\mathbf{5_d}$			9			r	-

(Continued on next page)

TABLE I Analytical and Spectral Data of the New Compounds (Continued)

December	Descript M D (OC)a	Viola	Mol form	Analyt	ical dat	Analytical data $({ m cal./found})^b$	$_q(\text{pun})$		
no	cryst. solvent	(%)	(mol. w.t.)	C	Н	N	S	IR $(\mathrm{Cm}^{-1})^c$	$\text{H-NMR}\ (\delta\ \text{ppm})^d$
8	310	20	$\mathrm{C}_{21}\mathrm{H}_{15}\mathrm{N}_{5}\mathrm{S}$	68.27	4.09	8.96	89.8	3350, 3344, 3212, 3112	11.0(s, 1H, NH), 8.3–7.7(m,
	(Dioxane)		(39.44)	68.54	4.23	8.88	8.92	$(2NH+NH_2)$.	13H, arom. + NH), 6.4–6.0(br, 2H, NH ₂).
9_{a}	288	06	$C_{22}H_{15}CIN_2O$	73.64	4.21	7.81		3221(NH), 1700(CO).	13.5(s, 1H, NH), 8.1–7.6(m,
င်္ခ	300	86	$C_{22}H_{15}CIN_{2}O$	73.64	4.21	7.81		3201(NH), 1702(CO).	14.5(s, 1H, NH), 8.2–7.3(m,
ì	(EtOH)		(358.86)	73.40	4.00	7.78			13H, arom.), 6.8(s, 1H, =CH).
$\mathbf{9_c}$	321	87	$\mathrm{C}_{22}\mathrm{H}_{15}\mathrm{CIN}_2\mathrm{O}$	73.64	4.21	7.81		3211(NH), 1700(CO).	11.5(s, 1H, NH), 8.1–7.6(m,
	(EtOH)		(358.86)	73.39	4.45	7.70			13H, arom.), 6.9(s, 1H, =CH).
$6^{\mathbf{q}}$	278	83	$C_{22}H_{15}N_3O_3$	71.54	4.09	11.38		3231(NH), 1702(CO).	12.5(s, 1H, NH), 7.9–7.2(m,
	(Acetic acid)		369.38	71.12	4.32	11.51			13H, arom.), 6.9(s, 1H, =CH).
9 e	244	92	$\mathrm{C}_{24}\mathrm{H}_{21}\mathrm{N}_3\mathrm{O}$	78.45	5.70	11.44		3221(NH), 1700(CO).	13.5(s, 1H, NH), 8.5–7.8(m,
	(EtOH)		(367.44)	78.22	5.65	11.23			13H, arom.), 7.4(s, 1H, =CH),
									$2.3(s, 6H, N(CH_3)_2].$
10	>330	26	$C_{23}H_{15}N_3O_2$	75.61	4.14	11.50		3321, 3231(2NH),	13.5(s, 1H, NH), 10.0(s, 1H,
	(DMF)		365.39	75.43	4.32	11.65		1720 isatine,	NH _{isatine}), 8.2–7.5 (m, 13H,
=	165	ά	Co.H. N.O.	74.43	9 70	15.78		3991(NH) 9180(CN)	13 0(s 1H NH) 10 9(s 1H
:	(EtOH)	3	(532.5)	74.12	3.55	15.54		0221(MII), 2100(OIN).	NH; NH; 800–7.2 (m, 18H,
									arom.).
$12_{\rm a}$	181	75	$\mathrm{C}_{20}\mathrm{H}_{16}\mathrm{N}_4\mathrm{S}$	69.74	4.68	16.27	9.31	$3221, 3168(NH_2), 2100$	8.6-7.0 (m, 9H, arom.),
	(EtOH)		(344.43)	69.56	4.60	16.46	9.50	(CN).	$6.4-6.0(br, 2H, NH_2),$
									2.2–2.0(q, 2H, CH ₂), 1.1–0.9(t,

7.6–7.0 (m, 9H, arom.), 5.4–5.0(br, 2H, NH_2), 4.3–4.0(q, 2H, CH_2 ester), 2.3–2.0 (q, 2H, CH_2), 1.1–0 of 4 3H CH_2),	<u>&</u>	∞.	211, CH2), 1.1—0.3(1, 311, CH3). 12.0(s, 1H, NH), 8.0—7.5(m, 14H, arom.), 5.5–5.1(br, 2H, NH ₂).	12.4(s, 1H, NH), 8.2–7.3(m, 14H, arom.), 5.4–5.0(br, 2H, NH ₂).	9.9(s, 1H, NH), 7.8–7.2(m, 15H, arom, + NH)	10.4(s, 1H, NH), 8.0-7.5(m, 14H, arom.), 5.2-4.9(br, 2H, NH2).	13.4(s, 1H, NH), 8.0 – 7.5(m, 13H, arom.), 5.0–4.6(br, 2H, NH ₂).
3331, 3240(NH ₂), 1730 (CO).	3331, 3300, 3210, 3145 (2NH ₂), 2230(2CN).	3350, 3310, 3230, 3185 (2NH ₂), 2170(CN), 1433 (CS).	3320, 3300, 3265(NH + NH ₂), 3166(NN) $\frac{1492}{1600}$	2193(CM), 1493(CG) 3330, 3300, 3235(NH + NH2), 9146(CM), 1433(CG)	3215, 3199(2NH), 2200 (CN), 1689(CO).	3387, 3215, 3199(NH, NH ₂), 2220 (CN), 1689(CO)	$3320, 3300, 320, 3265(\mathrm{NH} + \mathrm{NH}_2), 2169(\mathrm{CN}).$
8.19	7.81	11.75	7.45 7.17	7.16			
10.73	20.47 20.65	17.97 17.79	1.69	15.65 15.54	14.42	14.35	15.71 15.57
5.41	4.42	4.25	4.08	3.83	4.15	4.56	3.62
67.50 67.70	67.30 67.43	66.03 66.32	71.58 71.63	69.78 69.52	77.31	76.91	72.73 72.55
$ m C_{22}H_{21}N_{3}O_{2}S \ (391.49)$	C23H18N6S (410.50)	$ m C_{30}H_{23}N_7S_2 \ (545.8)$	$C_{25} H_{17} N_5 S \\ (419.50)$	$C_{26}H_{17}N_5OS$ (447.51)	$C_{25}H_{16}N_4O$ (388.43)	$C_{25}H_{18}N_4O$ (390.44)	$C_{27}H_{16}CIN_5 = (445.91)$
65	57	43	77	89	26	56	09
215 (Dioxan)	285 (EtOH)	>330 (DMSO)	295 (Dioxan)	341 (Dioxan)	300 (EtOH)	281 (EtOH)	311 (EtOH)
$12_{\rm b}$	13	14	16_{a}	$16_{\rm b}$	17	18	19

(Continued on next page)

TABLE I Analytical and Spectral Data of the New Compounds (Continued)

mol. w.t.) C H N S IR $(Cm^{-1})^c$ $C_{18}H_{12}N_4S$ 68.33 3.82 17.71 10.13 $3320, 3300,$ (316.38) 68.55 3.66 17.62 10.29 $3225(NH + NH_2),$ $C_{24}H_{18}N_6S_2$ 63.42 3.99 18.49 14.11 $3331, 3300, 3210, 3145$ (454.57) 63.64 3.82 18.60 14.37 $(2NH_2), 2130(CN),$ $C_{30}H_{23}N_7S$ 70.16 4.15 19.09 6.24 $3300, 3250, 3200, 3135$ (513.62) 70.36 4.36 19.26 6.46 $(2NH_2), 2130(CN),$ (513.62) 70.36 4.36 19.26 6.46 $(2NH_2), 2130(CN),$ (489.61) 68.44 3.80 14.12 13.31 $1422(CS).$ $C_{34}H_{24}N_6S$ 74.43 4.41 15.32 5.84 $2233, 2200 (2CN),$ (548.66) 74.21 4.19 15.02 5.71 $1422(CS).$ $C_{21}H_{20}N_2$	Droduet	M D (OC)a	Viold	mol form	Analyti	cal data	Analytical data $(cal./found)^b$	$_q(\mathrm{puno})$		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	no	cryst. solvent	(%)	(mol. w.t.)	C	Н	Z	w	IR $(\mathrm{Cm}^{-1})^c$	$\text{H-NMR}\ (\delta\ \text{ppm})^d$
301 86 C ₂₄ H ₁₈ N ₆ S ₂ 63.42 3.99 18.49 14.11 33_1,300,3210,3145 (Bnzene) (454.57) 63.64 3.82 18.60 14.37 (2NH ₂),2130(CN),1443(CS). 295 85 C ₃₀ H ₂₃ N ₇ S 70.16 4.15 19.09 6.24 3300,3250,3200,3135 (EtOH) 70.36 4.36 19.26 6.46 (2NH ₂), 2130(CN),1489 285 87 C ₂₈ H ₁₉ N ₅ S ₂ 68.69 3.91 14.30 13.10 2219, 2210(2CN),1483(CS). (EtOH) 77 C ₃₄ H ₂₄ N ₆ S 74.43 4.41 15.32 5.84 2233, 2200 (2CN),1648(CS). (EtOH) 548.66) 74.21 4.19 15.02 5.71 1422(CS). 311 65 C ₂₁ H ₂₀ N ₂ OS ₂ 66.29 5.30 7.36 16.85 2966, 2877(CH), 1704 (Dioxane) 390.52) 66.01 5.12 7.14 16.90 (CO).	20	175 (EtOH)	85	$C_{18}H_{12}N_4S$ (316.38)	68.33 68.55	3.82	17.71 17.62	10.13 10.29	$3320, 3300, \\ 3235(\mathrm{NH} + \mathrm{NH}_2), \\ 2221(\mathrm{CN})$	10.0(s, 1H, NH), 7.9–7.2 (m, 9H, arom.), 5.1(s, 2H, NH $_2$).
295 85 C ₃₀ H ₂₃ N ₇ S 70.16 4.15 19.09 6.24 3300, 3250, 3200, 3135 285 87 C ₂₈ H ₁₉ N ₅ S2 68.69 3.91 14.30 13.10 2219, 2210(2CN), 1433(CS). EtOH) 77 C ₃₄ H ₂₄ N ₆ S 74.43 4.41 15.32 5.84 2233, 2200 (2CN), 1422(CS). EtOH) 65 C ₂₁ H ₂₀ N ₂ OS ₂ 66.29 5.30 7.36 14.22 (CS). 311 65 C ₂₁ H ₂₀ N ₂ OS ₂ 66.01 5.12 7.14 16.90 (CO). Dioxane) 390.52) 66.01 5.12 7.14 16.90 (CO).	$21_{\rm a}$	301 (Bnzene)	98	$ m C_{24}H_{18}N_6S_2 \ (454.57)$	63.42 63.64	3.99	18.49 18.60	14.11 14.37	3331, 3300, 3210, 3145 (2NH ₂), 2130(CN), 1443(CS).	8.6–7.0 (m, 9H, arom.), 6.4–6.0(br, 2H, NH ₂), 5.1–4.6(br, 2HNH ₂), 2.2–2.0(q,
285 87 $C_{28}H_{19}N_5S_2$ 68.69 3.91 14.30 13.10 2219,2210(2CN), (EtOH) (489.61) 68.44 3.80 14.12 13.31 1422(CS). 287 77 $C_{34}H_{24}N_6S$ 74.43 4.41 15.32 5.84 2233,2200 (2CN), (EtOH) (548.66) 74.21 4.19 15.02 5.71 1422(CS). 311 65 $C_{21}H_{20}N_2OS_2$ 66.29 5.30 7.36 16.85 2966,2877(CH),1704 (Dioxane) (390.52) 66.01 5.12 7.14 16.90 (CO).	$21_{ m b}$	295 (EtOH)	85	$\substack{\text{C}_{30}\text{H}_{23}\text{N}_7\text{S}\\(513.62)}$	70.16 70.36	4.15	19.09 19.26	6.24	3300, 3250, 3200, 3135 (2NH ₂), 2130(CN), 1433(CS).	24, CH ₂), I.1–0.5(t, 5H, CH ₃). 8.5–7.3 (m, 14H, arom.), 6.0–5.6(br, 2H, NH ₂), 5.0–4.5(br, 2HNH ₂), 5.1–4.5(br, 2HNH ₂),
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$22_{ m a}$	285 (EtOH)	87	$C_{28}H_{19}N_5S_2 \\ (489.61)$	68.69 68.44	3.91	14.30 14.12	13.10 13.31	2219, 2210(2CN), 1422(CS).	2H, CH ₂), I.1—0.8(t, 5H, CH ₃). 8.3–7.3 (m, 9H, arom.), 2.2–2.0(q, 2H, CH ₂), 1.1–0.9(t,
311 65 $C_{21}H_{20}N_2OS_2$ 66.29 5.30 7.36 16.85 2966, 2877(CH), 1704 8.3 (Dioxane) (390.52) 66.01 5.12 7.14 16.90 (CO).	$22_{ m b}$	287 (EtOH)	77	$\mathrm{C_{34}H_{24}N_6S}$ (548.66)	74.43 74.21	4.41	15.32 15.02	5.84 5.71	2233, 2200 (2CN), 1422(CS).	3 H, CH ₃). 8.0–7.0 (m, 14H, arom.), 2.2–2.0(q, 2H, CH ₂), 1.1–0.9(t, 3H, CH ₂)
	23	311 (Dioxane)	65	$ m C_{21}H_{20}N_{2}OS_{2} \ (390.52)$	66.29 66.01	5.30	7.36	16.85 16.90	2966, 2877(CH), 1704 (CO).	8.3–7.3 (m, 9H, arom.), 8.5–2.4(m, 6H, 3CH ₂), 2.2–2.0(q, 2H, CH ₂), 1.1–0.9(t, 3H, CH ₃).

 $^{^{}a}$ Uncorrected.

^bSatisfactory microanalyses obtained; C, \pm 0.3%, H, \pm 0.3%, N, \pm 0.45%, S, \pm 0.21.

 $[^]cMeasured$ on Nicolet 710 FT-IR spectrophotometer. dMeasured with a Varian EM 360 L using TMS as internal standard.

compound 11 showed an absorption band corresponding to the CN group at 2219 $\rm Cm^{-1}$ (c.f. Scheme 2, Table I).

1,3-Dihydro-1-ethyl-4-phenyl-1,5-benzodiazepin-2-one $\mathbf{1_b}^{13}$ was allowed to react with elemental sulfur along with malononitrile, ethyl cyanoacetate, or 1,1,3-tricyano-2-aminoprop-1-ene to yield the corresponding thieno[3,2-b]benzodiazepines $\mathbf{12_{a,b}}$ and $\mathbf{13}$, respectively. Treatment of compound $\mathbf{13}$ with phenyl isothiocyanate¹⁴ in the presence of triethylamine as a base gave the corresponding 2-amino-3-pyrimidinyl thieno(3,2-b)-1,5-benzodiazepine derivative $\mathbf{14}$. The reaction pathway for the formation of compound $\mathbf{14}$ was assumed to proceed via a nucleophilic attack of the ethylenic NH₂ group to the C=S group followed by a nucleophilic addition of the formed NH group to the CN group (c.f. Scheme 3, Table I).

SCHEME 3

[1,3-Dihydro-4-phenyl(1,5)benzodiazepin-2-ylidene]malononitrile ${\bf 15}^8$ was treated with phenyl isothiocyanate, 15 benzoyl isothiocyanate, benzoyl chloride, 15 or benzaldehyde 15 in pyridine to give the corresponding pyrido(4,3-b)benzodiazepinethiones ${\bf 16_{a,b}}$, pyrido(4,3-b)benzodiazepinone ${\bf 17}$, or pyrano(4,3-b)benzodiazepine ${\bf 18}$, respectively. Moreover, treatment of compound ${\bf 15}$ with p-chlorobenzylidenemalononitrile 12 in the presence of triethylamine afforded the corresponding 3-amino-2,4-dicyanobenz[b]-(1,5)benzodiazepine

derivative **19**. Thieno[3,2-b]benzodiazepine **20** was synthesized through the reaction of compound **15** with elemental sulfur in the presence of triethylamine (c.f. Scheme 4, Table I).

SCHEME 4

Compound $\mathbf{1}_b$ was allowed to react with a mixture of CS_2 or PhNCS and 1,1,3-tricyano-2-aminoprop-1-ene under PTC conditions (dioxane/ K_2CO_3 /tetrabutylammonium bromide [TBAB]) to afford pyridothiopyrano[4,3-b]-1,5-benzodiazepine $\mathbf{21}_a$ and [1,5]-benzodiazepino[6,5-c][1,8]naphthyridine $\mathbf{21}_b$, respectively. The reaction pathway¹⁶ was indicated in Scheme 5. Also, treatment of compound $\mathbf{1}_b$ with a mixture of CS_2 or PhNCS and 2(1-methylthio-1'-anilinomethyl-idene)malononitrile¹² under PTC conditions afforded the corresponding 1,3-thiazino(4,5-b)-1,5- benzodiazepine $\mathbf{22}_a$ and

pyrimido-1,5-benzodiazepine 22_b derivatives, respectively. Morever, the reaction of compound 1_b with CS_2 and 1,3-dibromopropane in a 1:1:1 molar ratio under the same PTC conditions afforded the corresponding 3[1,3-dithi-2-ylidene]benzodiazepin-2-one derivative 23 (c.f. Scheme 5, Table I).

SCHEME 5

EXPERIMENTAL

All melting points were determined on a Koffler melting points apparatus and are uncorrected. IR spectra were obtained on a Nicolet 710

FT-IR spectrometer. ¹H-NMR spectra were recorded on a Varian EM 360 at 60 MHz using TMS as an internal reference and DMSO-d₆ as a solvent. Elemental analyses were performed on a perkin-Elmer CHN-2400°C analyzer model.

Synthesis of Compounds 2_{a-d}

A mixture of compound $\mathbf{1_a}$ (0.01 mol, 2.36 gm), the appropriate arylidenecyanothioacetamide (0.01 mol), including benz[b]-3,4-dioxolmethylidene- (2.32 g), p-fluorobenzylidene- (2.06 g), thiene-2-ylidene- (1.94 g), or pyrrol-2-ylidenecyanothioacetamide (1.77 g), and catalytic amount of piperidine (0.2 mL) was refluxed in dioxane (20 mL) for 2 h. The formed precipitate was filtered off and crystallized from an appropriate solvent to give compounds $\mathbf{2_{a-d}}$ (cf. Scheme 2, Table I).

Synthesis of Compounds 3_{a-d} (Method A)

The appropriate compound $\mathbf{2}_{\mathbf{a-d}}$ (0.01 mol) was suspended in sodium ethoxide solution (0.23 g Na in 30 mL absolute ethanol) and refluxed for 3 h. The solid that formed after cooling was collected by filteration, washed with water, and crystallized from the suitable solvent to give the compounds $\mathbf{3}_{\mathbf{a-d}}$ (cf. Scheme 2, Table I).

Synthesis of Compounds 3_{a-d} and 4 (Method B)

A mixture of compound $\mathbf{1_a}$ (0.01 mol, 2.36 gm), the appropriate ylidenecyanothioacetamide (0.01 mol), and sodium ethoxide (0.23 g of Na in 40 mL absolute ethanol) was refluxed for 2 h. The formed precipitate was filterd off, dried, washed with water, and crystallized from an appropriate solvent to give compounds $\mathbf{3_{a-d}}$ and $\mathbf{4}$, respectively (cf. Scheme 2, Table I).

Synthesis of Compounds 5_{a-d}

A mixture of compound $\bf 3_a$ (0.005 mol, 4.48 gm), (0.005 mol) from the appropriate halo compound (chloroacetonitrile [0.31 mL], ethyl chloroacetate [0.54 mL], phenacyl bromide [0.93 g] or chloroacetanilide [0.85 g]) and sodium acetate (0.005 mol, 0.41 gm) in ethanol (20 mL) was refluxed for 2 h. The precipitate that was obtained was filtered off, washed with water, and crystallized from the appropriate solvent to give the compounds $\bf 5_{a-d}$, respectively (cf. Scheme 2, Table I).

Synthesis of Compound 6

Compound $\mathbf{5_a}$ (0.01 mol, 5.34 g) was suspended in sodium ethoxide solution (0.35 g Na in 30 mL absolute ethanol) and refluxed for 3 h. The solid that formed after cooling was filtered off, washed with water, and crystallized from the ethanol to give the compound $\mathbf{6}$ (cf. Scheme 2, Table I).

Synthesis of Compounds 7 and 8: General Procedure

To a stirred solution of compound $\mathbf{1_a}$ (0.003 mol, 0.7 g) in methanol (25 mL), thiophene-2-aldehyde (0.003 mol, 0.28 mL), thiourea (0.003 mol, 0.22 g) or guanidine hydrochloride (0.003 mol, 0.28 g) and sodium methoxide (0.23 g Na in 5 mL methanol) were added. The reaction mixture was refluxed for 2 h, evaporated *in vacuo* and the residue was triturated with pet. ether (60–80°C). The solid product was collected by filtration and crystallized (cf. Scheme 2, Table I).

Synthesis of Compounds 9 and 10: General Procedure

A mixture of compound $\mathbf{1_a}$ (4.72 g, 0.005 mol); the appropirate carbonyl reagent (0.005 mol), including o-chloro- (0.7 g), m-chloro- (0.7 g), p-hloro- (0.7 g), p-nitro- (0.75 g), p N,N-dimethylaminobenzaldehyde (0.73 g), or isatin (0.73 g); and fused sodium acetate (2.3 g) in glacial acetic acid (20 mL) was refluxed for 4 h. On cooling, the precipitated solid was filtered, dried, washed with water, and crystallized from appropirate solvent (cf. Scheme 2, Table I).

Synthesis of Compound 11

Equimolar amount (0.003 mol) of compound **10** (0.28 g) and 2(1-methylthio-1'-anilinomethylidene)malononitrile (0.64 g) were dissolved in *tert*. butanol (30 mL) containing few drops of triethyl amine. The reaction mixture was refluxed until the evolution of MeSH ceased (12 h), evaporated *in vacuo*, and the remaining residue was triturated with pet. ether (40–60 $^{\circ}$ C). The solid formed was collected by filtration and crystallized (cf. Scheme 2, Table I).

Synthesis of Compounds 12 and 13: General Procedure

A mixture of compond $\mathbf{1}_b$ (0.002 mol, 0.53 g); elemental sulfur (0.002 mol, 0.096 g); the appropirate active methylene (0.003 mol) including malononitrile (0.1 g), ethyl cyanoacetate (0.23 mL), or 1,1,3-tricyano-2-aminoprop-1-ene (0.26 g), and triethylamine (0.003 mol,

0.32 mL) in dioxane (20 mL) was refluxed for 3 h. The solid that formed on cooling was filtered off and crystallized from an appropriate solvent (cf. Scheme 3, Table I).

Synthesis of Compound 14

A mixture of compound **13** (0.002 mol, 0.82 g), phenyl isothiocyanate (0.002 mol, 0.23 mL), and a catalytic amount of triethylamine was refluxed in dimethylformamide (20 mL) for 2 h. The formed precipitate was filtered off and crystallized to give compound **14** (cf. Scheme 3, Table I).

Synthesis of Compounds 16_{a,b}-18: General Procedure

Equimolar amounts (0.003 mol) of compound 15 (0.89 g) and phenyl isothiocyanate (0.35 mL), benzoyl isothiocyanate (0.4 mL), benzoyl chloride (0.34 mL) or benzaldehyde (0.32 mL) in pyridine (20 mL) was refluxed for 5 h. After cooling, the reaction mixture was poured into a mixture of ice water (100 mL) and HCl (5 mL). The separated solid was then collected by filtration, washed with water, and crystallized from appropirate solvent (Scheme 4, Table I).

Synthesis of Compounds 19

(0.003 Mol) of compound **15** (0.89 g), *p*-chlorobenzylidene-malononitrile (0.7 g), and triethylamine (0.2 mL) in dioxane (20 mL) was refluxed for 4 h. On cooling, the precipitated solid was filtered off, dried, and crystallized (cf. Scheme 4, Table I).

Synthesis of Compound 20

A mixture of compound **15** (0.003 mol, 0.89 g), elemental sulfur (0.003 mol, 0.1 g), and a catalytic amount of triethylamine was refluxed in dioxane (20 mL) for 2 h. The formed precipitate was filtered off and crystallized to give compound **20** (cf. Scheme 3, Table I).

Synthesis of Compounds 21-23: General Procedure

A mixture of anhydrous potassium carbonate (3 g), dry dioxane (30 mL), compound $\mathbf{1_b}$ (0.003 mol, 0.79 g), carbon disulfide (0.003 mol, 0.22 mL) or phenyl isothiocyanate (0.003 mol, 0.36 mL) and TBAB (0.003 g) was stirred for 2 h. at room temperature and stirred for 2 h at 60°C. To the

reaction mixture, the appropirate reagent (0.003 mol), namely, 1,1,3-tricyano-2-aminoprop-1-ene (0.39 g), 2(1-methylthio-1'-anilinomethylidene)malononitrile (0.64 g), or 1,3-dibromopropane (0.6 mL), was added. The reaction mixture was stirred for 5 h at 60°C until the completion of the reaction (TLC). The reaction mixture was filtered off and the filtrate evaporated in vacuo. The residual solid was washed with water and then crystallized from the appropriate solvent (cf. Scheme 5, Table I).

REFERENCES

- [1] E. Teboul and G. Chauinard, Can. J. Psychiatr., 36, 62 (1991).
- [2] S. D. Gatzonis, E. K. Angelopoulos, E. G. Daskalopoulou, V. Mantouvalos, A. Chioni, C. Zorrunas, et al., *Drug and Alcohol Dependence*, **59**, 95 (2000).
- [3] K. Matsumoto, S. I. Kohno, K. Ojima, and H. Watanabe, Brain Res., 754, 325 (1997).
- [4] Q. Huang, R. Liu, X. He, R. McKernan, T. Gan, D. W. Bennett, et al., J. Med. Chem., 41, 4130 (1998).
- [5] K. Toshiyuki, T. Hiroshi, K. Koreichi, H. Hideki, S. Kohji, A. Masafumi, et al., J. Heterocycle Chem., 39, 163 (2002).
- [6] C. M. Beasley, G. Tollefson, P. Tran, W. Satterlee, T. Sanger, and S. Hamilton, Neuropsychopharmacology, 14, 111 (1996).
- [7] H. Abdel-Ghany, A. M. El-Sayed, A. Khodairy, and H. Salah, Synthetic Comm., 31, 2523 (2001).
- [8] A. Khodairy, A. M. El-Sayed, H. Abdel-Ghany, and H. Salah, J. Chinese Chem. Soc. 50, 1195 (2003).
- [9] W. Ried and P. Stahlhofen, Chem. Ber., 90, 825, (1957).
- [10] A.-B. A. G. Ghattas, A. Khodairy, M. A. Abd-Rahman, and S. Younes, *Phosphorous, Sulfur and Silicon*, 178, 1781 (2003).
- [11] A. Perjesi, G. Batta, and A. Foldesi, Monatsh. Chem., 125, 433 (1994).
- [12] A. Khodairy, Phosphorous, Sulfur, and Silicon, 160, 159 (2002).
- [13] H. Abdel-Ghany, A. M. El-Sayed, A. A. Sultan, and A. K. El-Shafei, Synth. Comm., 20, 893 (1990).
- [14] S. M. Sherif, W. W. Wardakhan, and R. M. Mohareb, J. Chem. Res. (S) 356 (1996), J. Chem. Res (M), 1970 (1996).
- [15] A. M. El-Sayed and H. Abdel-Ghany, J. Hetero. Chem., 37, 1233 (2000).
- [16] A. M. M. El-Saghier, Phosphorous, Sulfur, and Silicon, 177, 1213 (2002).